Cepheid (NASDAQ:CPHD) is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for testing in the clinical market, as well as for application in the Company's legacy Industrial, Biothreat and Partner markets. Cepheid achieved its new 52 week high price of $43.47 where it was opened at $40.80 UP 8.79 points or +25.59% by closing at $43.14.

Cepheid (NASDAQ:CPHD) witnessed volume of 3.12 million shares during last trade however it holds an average trading capacity of 769,181.00 shares. CPHD last trade opened at $37.70 reached intraday low of $34.90 and went -3.19% down to close at $37.32.

Read Full Article and Disclaimer at :http://crwewallstreetnewsalert.com/?p=6054

**athenahealth, Inc. (ATHN) reported results for the second quarter of fiscal year 2011, with total revenue increased 33 percent year over year. ATHN also announced the signing of a definitive agreement to acquire Proxsys LLC which is focused on the front end of the revenue cycle for hospital systems.

***************************************